
ENPICOM offers a unified bioinformatics platform designed to accelerate biologics discovery and engineering for AI and lab scientists. The platform integrates best-in-class bioinformatics, a scalable data foundation, and advanced ML frameworks. It focuses on data foundation, workflow automation, and AI integration, enabling faster lead selection and optimized candidate development. ENPICOM's solutions simplify analysis, streamline decision-making, and provide direct access to AI models, advanced developability assessment tools, and support for various research phases like hit selection and enrichment analysis. The company emphasizes seamless integration into existing data ecosystems via a comprehensive API and works with clients to deliver tailored solutions. ENPICOM aims to maximize the return on AI investments by fostering collaboration between data and lab scientists, reducing redundant tasks, and speeding up model development.

ENPICOM offers a unified bioinformatics platform designed to accelerate biologics discovery and engineering for AI and lab scientists. The platform integrates best-in-class bioinformatics, a scalable data foundation, and advanced ML frameworks. It focuses on data foundation, workflow automation, and AI integration, enabling faster lead selection and optimized candidate development. ENPICOM's solutions simplify analysis, streamline decision-making, and provide direct access to AI models, advanced developability assessment tools, and support for various research phases like hit selection and enrichment analysis. The company emphasizes seamless integration into existing data ecosystems via a comprehensive API and works with clients to deliver tailored solutions. ENPICOM aims to maximize the return on AI investments by fostering collaboration between data and lab scientists, reducing redundant tasks, and speeding up model development.
What they do: Unified bioinformatics platform to accelerate biologics discovery and engineering with data foundation, workflow automation, and AI/ML integration
Headquarters: 's-Hertogenbosch, The Netherlands
Founded: 2015
Founders / CEO: Alvise Trevisan; Jos Lunenberg (co-founder & CEO); Nicola Bonzanni
Growth financing rounds announced 2022–2024 with participation from BOP Capital / BOP Impact Ventures, BOM Brabant Ventures, NextGen Ventures, Arches Capital
| Company |
|---|
Biologics and antibody discovery, bioinformatics data management, ML-enabled candidate selection and developability assessment
2015
Biotechnology Research
Announced to scale IGX Platform and support customer growth (company press release)
Extended financing with participation from BOP Capital, BOM Brabant Ventures, NextGen Ventures, and Arches Capital
Additional growth capital from BOP Impact Ventures and BOM Brabant Ventures; new individual investor participation announced
“Participating investors include BOP Capital / BOP Impact Ventures, BOM Brabant Ventures, NextGen Ventures, Arches Capital and individual investor Dr. Colby Souders”